Mean general wellbeing scores of controls and patients with multiple sclerosis (MS)
| Stage I | Stage II | Stage III | p Value | Patients with MS | Control | p Value | |
|---|---|---|---|---|---|---|---|
| France (n) | 30 | 29 | 28 | 87 | 24 | ||
| Median | 50 | 25 | 25 | 0.00364-150 | 25 | 75 | 0.00014-150 |
| Q1/Q3 | 0/75 | 0/50 | 0/25 | 0/50 | 75/75 | ||
| Min–max | 0–100 | 0–100 | 0–75 | 0–100 | 50–100 | ||
| Germany (n) | 30 | 29 | 29 | 88 | 28 | ||
| Median | 75 | 25 | 25 | 0.00374-150 | 50 | 75 | 0.00014-150 |
| Q1/Q3 | 25/75 | 25/50 | 0/50 | 25/75 | 62.5/87.5 | ||
| Min–max | 0–100 | 0–100 | 0–75 | 0–100 | 25–100 | ||
| United Kingdom (n) | 28 | 24 | 27 | 79 | 27 | ||
| Median | 50 | 25 | 25 | 0.01114-150 | 25 | 75 | 0.00014-150 |
| Q1/Q3 | 25/75 | 0/50 | 0/50 | 0/50 | 50/75 | ||
| Min–max | 0–75 | 0–75 | 0–75 | 0–75 | 25–100 |
↵4-150 Wilcoxon test.